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Abstract
Background:  Congenital fibrosis of the extraocular muscles type 1 (CFEOM1) is an autosomal
dominant eye movement disorder linked to the pericentromere of chromosome 12 (12p11.2 -
q12).  Sarcospan  is  a  member  of  the  dystrophin  associated  protein  complex  in  skeletal  and
extraocular muscle and maps to human chromosome 12p11.2. Mutations in the genes encoding
each  of  the other components of the  skeletal  muscle  sarcospan-sarcoglycan complex (α  - δ
sarcoglycan)  have  been  shown  to  cause  limb  girdle  muscular  dystrophy  (LGMD2C-F).  To
d e t e r m i n e  w h e t h e r  m u t a t i o n s  i n  t h e  s a r c o s p a n  g e n e  a r e  r e s p o n s i b l e  f o r  C F E O M 1  w e :  ( 1 )
attempted to map sarcospan to the CFEOM1 critical region; (2) developed a genomic primer set
to directly sequence the sarcospan gene in CFEOM1 patients; and (3) generated an anti-sarcospan
antibody to examine extraocular muscle biopsies from CFEOM1 patients.
Results:  When tested by polymerase chain reaction, sarcospan sequence was not detected on
yeast or bacterial artificial chromosomes from the CFEOM1 critical region. Sequencing of the
sarcospan gene in CFEOM1 patients from 6 families revealed no mutations. Immunohistochemical
studies of CFEOM1 extraocular muscles showed normal levels of sarcospan at the membrane.
Finally,  sarcospan  was  electronically  mapped  to  bacterial  artificial  chromosomes  that  are
considered to be outside of the CFEOM1 critical region.
Conclusions:  In this report we evaluate sarcospan as a candidate gene for CFEOM1. We have
found that it is highly unlikely that sarcospan is involved in the pathogenesis of this disease. As of
yet no sarcospan gene mutations have been found to cause muscular abnormalities.
Background
CFEOM1 is an autosomal dominant disorder that has
been linked to the pericentromere of chromosome 12,
flanked by marker D12S1584 on the p arm and D12S1668
on the q arm [1, 2]. The clinical phenotype consists of
congenital, bilateral ptosis and external ophthalmople-
gia, with the eyes partially or completely fixed in a hypo-
trophic or downward position. On autopsy, CFEOM1
patients appear to be lacking the superior division of cra-
nial nerve III, which innervates the levator and superior
rectus muscles [3]. Whether this disease is caused by a
primary defect in the nerve or the muscle remains un-
clear. The disease was initially linked to an 8 centiMor-
gan region spanning the centromere of chromosome 12,
and then further refined to a critical region of 3 cM [1, 2].
Yeast and bacterial artificial chromosome (YAC and
BAC) contigs have been generated and a positional clon-
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ing approach to identify the CFEOM1 causative gene is
ongoing.
Sarcospan is a member of the dystrophin associated pro-
tein complex present in skeletal and extraocular muscle
[4,5,6]. Sarcospan is most tightly associated with the
transmembrane sarcoglycan subcomplex, mutation of
which causes autosomal recessive limb girdle muscular
dystrophy (LGMD2C-2F) [7,8,9,10,11]. Primary muta-
tion of α  - δ  sarcoglycan leads to a variable degree of sec-
ondary instability of sarcospan and the non-mutant
sarcoglycans. Sarcospan is homologous to the tet-
raspanin superfamily, members of which have been
shown to facilitate both integral-membrane and mem-
brane-proximal protein interactions involved in many
different cellular processes [12]. Sarcospan had previ-
ously been identified as Krag, a gene that is co-amplified
with Ki-ras in the Y1 murine adrenal carcinoma cell line
[13, 14]. Portions of the gene's genomic structure were
elucidated at that time, and the gene was localized to
chromosome 12p11.2.
Given the genomic localization of sarcospan in the criti-
cal region defined for CFEOM1, and its association with
other proteins known to be involved in muscular diseas-
es, sarcospan has been proposed as a candidate disease
gene for CFEOM1 [5]. We have refined the previously
published genomic structure of sarcospan more fully and
screened for mutations in six families with CFEOM1. We
have also generated antibodies that recognize human
sarcospan and examined extraocular muscle samples
from CFEOM1 patients.
We find sarcospan to be unmutated in all six CFEOM1
families studied and sarcospan immunoreactivity to be
identical in control and CFEOM1 extraocular muscle.
Sarcospan is also shown to map electronically to BACs
that are considered to be outside of the CFEOM1 critical
region. These data make it unlikely that sarcospan, or
other dystrophin associated proteins, are involved in the
pathogenesis of CFEOM1.
Results
Genomic organization of the human sarcospan gene
Five independent clones were isolated from a human ge-
nomic phage library using hybridization probes that cov-
ered the entire coding region of sarcospan. Primers
within the coding sequence were designed to cross the
two known intron-exon junctions and other hypothe-
sized junctions. The sarcospan open reading frame is en-
coded by three exons. The first exon contains 279 base
pairs (bp) of coding sequence and is extremely G/C rich
(71%). The second exon, as previously determined, is 87
bp in length. The third exon is very large and includes the
last 363 bp of coding sequence and over 1500 bp 3'-un-
translated region (UTR).
Analysis of the CFEOM1 critical region
Based on its cytogenetic localization and expression pat-
tern, sarcospan is a candidate gene for autosomal domi-
nant CFEOM1. Initially, to determine whether sarcospan
was contained on YACs or BACs spanning the CFEOM1
critical region, YACs 766h7, 762e1, 951h6, 813h9, 782e8,
813g11, 832f4, 887g10, 916c8, 936f5, 946d5, 852c3,
723h3, 906f9, 798b12, 958b2, 943f6, 957b8, and 973h3
[2] and BACs B455J16, B50I19, B459A22, B392F18,
B193D8, B855O3, B460N10, B351C12, B56H16,
B937H2, B1035D8, B251K10, B152M7, B396F22,
B45D10, B471G7, B520I18, and B367O10 (AECOM Ge-
nome Center Home Page chromosome 12 maps [http://
sequence.aecom.yu.edu/chr12/QARM1.pdf and http://
sequence.aecom.yu.edu/chr12/Parm2.pdf]) were tested.
Positive control primers were able to amplify fragments
of the YACs and BACs while sarcospan primers were not
(data not shown).
Mutation Analysis
Although the coverage of the YAC and BAC physical
maps was nearly complete, only direct sequencing of
CFEOM1 patient DNA would yield definitive results
about the status of the sarcospan gene in CFEOM1. Prim-
er pairs to amplify all of exon 2 and the coding portions
of exons 1 and 3 were designed. Because of the large 3'-
UTR present in exon 3, a primer pair was designed to
amplify the coding portions of the exon including the 5'
splice junction and 40 bp of 3' non-coding sequence (Fig-
ure 1).
Two affected individuals from each of six families with
CFEOM1 were analyzed by direct sequencing. No muta-
tions or polymorphisms were found.
Immunofluorescence Analysis
Samples of CFEOM1 affected and unaffected extraocular
muscle were analyzed for the pattern of sarcospan stain-
ing. Muscle was simultaneously stained with anti-spec-
trin antibody so that the samples' membrane integrity
could be assessed, and a comparison could be made be-
tween the levels of sarcospan in normal and CFEOM1
samples. All samples showed normal sarcolemmal stain-
ing; no abnormalities were observed (Figure 2).
BAC Mapping of Sarcospan
Comparison of the sarcospan coding sequence (GenBank
accession number AF016028) to the human genome se-
quence revealed that sarcospan is contained on the BACs
B283G6 and B612B6                                (Chromosome 12p
map page 1 [http://sequence.aecom.yu.edu/chr12/
Parm2.pdf]). These BACs are located 48.1 cM from theBMC Genetics (2001) 2:3 http://www.biomedcentral.com/1471-2156/2/3
telomere of 12p, while the CFEOM1 critical region is be-
tween 53.3 and 56.5 cM (Chromosome 12p map page 3
(search for D12S1584) [http://sequence.aecom.yu.edu/
chr12/Parm2.pdf] and Chromosome 12q map page 1
(search for D12S1668) [http://sequence.aecom.yu.edu/
chr12/QARM1.pdf]), thus placing sarcospan outside of
the CFEOM1 critical region.
Discussion
The critical region for the congenital eye movement dis-
order, CFEOM1, has been reduced to a 3 cM region at the
centromere of human chromosome 12 [2]. In an effort to
identify the gene which when mutated gives rise to
CFEOM1, a combination of positional and candidate
gene approaches has been undertaken. The sarcospan
gene is composed of three exons that are located on hu-
man chromosome 12p11.2 and the sarcospan protein has
been shown to be an integral component of the sarcogly-
can complex [5, 15, 16]. Mutations in any one of the other
four members of this complex have been shown to cause
muscular dystrophy. As the extraocular muscle is one of
the few muscles spared in Duchenne Muscular Dystro-
phy, the dystrophin associated protein complex present
in extraocular muscle may respond differently to muta-
tion of the complex than other striated muscle [17, 18].
By virtue of its genomic localization and expression in
extraocular muscle, sarcospan is a candidate gene for au-
tosomal dominant CFEOM1. We therefore chose to study
sarcospan more closely within the context of this disease.
Immunofluorescence data showed comparable patterns
of sarcospan staining in CFEOM1 and control patient
samples implying that there was no haplo-insufficiency,
altered accumulation or increased degradation of the
sarcospan protein in these patients. Direct sequencing of
the three coding exons of sarcospan in CFEOM1 patients
confirmed that they were normal, rendering alteration of
the sarcospan protein as the primary genetic defect in
CFEOM1 unlikely. This conclusion is supported by the
electronic localization of sarcospan to BACs outside of
the CFEOM1 critical region.
The normal staining pattern of sarcospan in the auto-
somal dominant CFEOM1 patient muscle indicates that
the primary genetic mutation is likely to be found in an-
other, unrelated gene. Patients with autosomal domi-
nant limb girdle muscular dystrophy type 1C, caused by
mutations in caveolin-3 [19, 20], or autosomal recessive
LGMD2B, caused by mutations in dysferlin, show nor-
mal dystrophin and sarcoglycan-sarcospan complex
staining patterns [21]. Sarcospan immunoreactivity is al-
tered in both Duchenne Muscular Dystrophy and the sar-
coglycanopathies (LGMD2C-F) and appears to be very
sensitive to disturbances in the dystrophin associated
protein complex [16]. Thus the finding that sarcospan is
normal in CFEOM1 patient muscle suggests that sar-
cospan itself and the rest of the dystrophin associated
protein complex are not involved in the pathogenesis of
the disease.
A sarcospan null mouse has recently been generated and
appears to display a normal phenotype [22]. This does
not, however, rule out the possibility of sarcospan play-
ing a primary role in a muscle disorder. There may, for
example, be a homologous tetraspanin protein that com-
pensates for the absence of sarcospan in mice, but not in
humans. There is, of course, also a difference between
complete absence of a protein and a protein with an al-
tered sequence. This may hold especially true, as sar-
cospan appears to be member of the tetraspanin family
of proteins, which have been described as molecular fa-
cilitators; alterations of such a protein's sequence could
affect the proteins with which it interacts. We are there-
fore expanding our patient analysis to include patients
with other forms of muscular abnormalities including
unlinked muscular dystrophies.
The effort to identify the CFEOM1 disease gene is contin-
uing with analysis of other genes and expressed sequence
tags from the critical region at the centromere of chro-
mosome 12.
Conclusions
The DNA sequence analysis and protein immunofluores-
cence results that show sarcospan to be normal in
CFEOM1 patients, combined with the localization of sar-
cospan to BACs that are outside of the CFEOM1 critical
region, make it unlikely that sarcospan is involved in
CFEOM1.
Figure 1
Schematic representation of the genomic organization of human sarcospan. Exons are indicated by solid boxes, the 3'-UTR by
a dashed box, and introns by a solid line. The exact size of the first intron is not known; the second intron is approximately 6
kb. Genomic primers are represented by arrows showing their position relative to intron/exon borders and coding sequences.
ATG TAABMC Genetics (2001) 2:3 http://www.biomedcentral.com/1471-2156/2/3
Figure 2
Sarcospan staining of CFEOM1 and unaffected extraocular muscle. Sarcospan is present at the membrane of extraocular mus-
cle from CFEOM1 (A) and unaffected control (B) patients. Spectrin is also shown as an indicator of membrane integrity (C, D).BMC Genetics (2001) 2:3 http://www.biomedcentral.com/1471-2156/2/3
Materials and Methods
Screening of Human Genomic DNA Library
Two hybridization probes spanning the entire sarcospan
coding sequence were generated by PCR amplification of
sarcospan cDNA amplifying 366 bp (5'-ATGGGCAA-
GAACAAGCAGCCACG-3' and  5'-TTTCATAGAAAATT-
GAATACATGTCC-3') and 466 bp (5'-
GGGCTGGGATCATTGTCTGCT-3' and 5'-GGAATTCT-
TAGATCTTTTGCTGGGG-3'). The bands were excised
from 0.8% low-melt agarose and 20 ng of DNA were la-
beled with [α -32P]-dCTP using the Life Technologies
Random Primers DNA Labeling System. A human ge-
nomic phage library (Clontech) was screened by hybrid-
ization with the radiolabeled products according to
standard protocols. Briefly, filters were pre-hybridized at
65° C in hybridization buffer (5x SSC, 50 mM NaPO4, pH
7.4, 2.5x Denhardt's Solution) with 100 µ g/ml denatured
salmon sperm DNA for two hours. Probes were dena-
tured at 95° C for 5 minutes and added to fresh hybridiza-
tion buffer at 200,000 cpm/ml buffer for 16 hours.
Following three one-hour washes in 2x SSC, 0.1% SDS,
filters were exposed for 18 - 100 hours. Positively hybrid-
izing plaques were purified by limiting dilution and
phage DNA was isolated and purified with the Lambda
Maxi Kit (Qiagen).
Determination of intron-exon boundaries
Five unique, partially overlapping genomic phage clones
were identified. Phage DNA was sequenced with exon
specific primers on an ABI automated sequencer. Ac-
quired data was analyzed with the Sequencher software
(Genecodes). The intron-exon borders were defined by
divergence of the cDNA and genomic sequences, and by
their adherence to splice donor and acceptor consensus
sequences.
Patient material
Genomic DNA extracted from blood was used to screen
two affected family members from each of six previously
described pedigrees [1, 2]. The patients included in our
analysis are AIII13, AIV1; BII4, BIV1; HIII17, HIII19;
AAIII5, AAIII10; ACIV5, ACV1; and ADIII3, ADIII8. Ex-
traocular muscle (inferior rectus) from patient AVI1 was
obtained during a diagnostic biopsy. Age match control
extraocular muscle (inferior rectus) from an unrelated,
unaffected individual was obtained during an autopsy.
This study was approved by the Children's Hospital insti-
tutional review board, and informed consent was ob-
tained from all adult participating subjects and from
parents or legal guardians of participating minors.
YAC and BAC maps
Development of the YAC map was described previously
by Engle, et al. [1]. BACs were isolated from RPCI-11
male and RPCI-13 female BAC libraries as described [23,
24].
PCR amplification from YAC contig
Primers from exons 1 and 3 were used to test the YACs
from the critical region defined for CFEOM1. The exon 1
primers amplified a 116 bp fragment (5'-AAGGAGTGCG-
GGGAGGAG-3' and 5'-GCCATGAGGAAGCCCACC-3')
and the exon 3 primers amplified a 150 bp fragment (5'-
TTTGCCGCCCACCACTATTC-3' and 5'-TGAAAGT-
GCCAGTGACGC-3'). A total of 28 cycles (94° C /1
minute; 57° C/1 minute; 72° C/1 minute) following a 4
minute denaturation was used.
PCR amplification from BAC contig
Primers for exons 2 and 3 were used to test the BACs
from the critical region defined for CFEOM1. Amplifica-
tions were performed as described below. Positive con-
trol reactions included template DNA isolated from
human genomic phage that contained the appropriate
sarcospan exons, and primers from the markers used to
order the BAC map to ensure the quality of the DNA. Re-
actions were analyzed on agarose gels and scored for
presence or absence of the appropriately sized product.
Primer sets and PCR conditions for direct sequencing
Three primer pairs amplifying the coding portions of ex-
ons 1 and 3 and all of exon 2 were designed (Table 1). Op-
timal polymerase chain reaction conditions were
determined for each of the sets using 60-100 ng genomic
DNA. Optimal buffer conditions for the exon 1 primer set
were obtained with the FailSafe PCR PreMix Selection
Kit (Epicentre Technologies) and Buffer F was used in
conjunction with the FailSafe PCR Enzyme mix. PCR
amplifications were performed in a 50 µ l reaction vol-
ume with 60-100 ng genomic DNA, 200 µ M of each
dNTP and 1.25 units PCR enzyme mix. A total of 35 cy-
cles (94° C/20 sec; 61° C/20 sec; 72° C/30 sec) following a
4 minute denaturation step was used. Exons 2 and 3 were
amplified using PfuTurbo polymerase (Stratagene) at 2.5
Units per 50 µ l reaction, containing 5 µ l of the accompa-
nying 10x PCR buffer, 200 µ M of each dNTP, 100 ng of
each primer and 60-100 ng genomic DNA. A total of 35
cycles (94° C/20 sec; 56° C/20 sec; 72° C/1 min) was used
to amplify both exons 2 and 3. PCR amplification prod-
ucts were purified using the QIAquick PCR Purification
Kit (Qiagen) and both strands were sequenced on an ABI
automated sequencer. Data was analyzed with the Se-
quencher software (Genecodes).
Antibodies
Anti-human-sarcospan antibodies were generated by
subcutaneous injection of New Zealand white rabbits
with the synthetic N-terminal peptide MG-
KNKQPRGQQRQGGC (QCB). The final amino acid wasBMC Genetics (2001) 2:3 http://www.biomedcentral.com/1471-2156/2/3
added for purification purposes. The resulting serum
was purified over a peptide affinity column made by cov-
alent coupling of the unlinked peptide to SulfoLink beads
(Pierce). Anti-human spectrin antibodies (NCL-SPEC1)
were obtained from Vector Laboratories.
.
Immunofluorescence Analysis
CFEOM1 patient and normal muscle sections from ex-
traocular muscle were stained with anti-human sar-
cospan and anti-human spectrin antibodies. Sections
were fixed for 1 minute in ice cold methanol; blocked for
45 minutes in blocking buffer (15% horse serum, 0.025%
Triton, 1x PBS); incubated overnight at 4° C with anti-
sarcospan (1:750) and anti-spectrin (1:100) antibodies in
block buffer; washed 3 ×  for 15 minutes in wash buffer
(0.025% Triton, 1x PBS); incubated for 2 hours at 4° C
with Cy3 conjugated anti-rabbit secondary antibody
(Jackson ImmunoResearch) and Alexa-488 conjugated
anti-mouse secondary antibody (Molecular Probes Inc.)
diluted 1:300 in blocking buffer; washed 3 ×  for 15 min-
utes in wash buffer and mounted with Immumount
(Shandon). Samples were examined using a Zeiss Axio-
phot microscope.
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